News

Encore Vision president and CEO Bill Burns said: "We are pleased to confirm that 75 subjects have been enrolled in the study and to date, there have been

Data generated from the analysis are expected to expand the understanding of multiple myeloma biology and potentially identify mechanisms of sensitivity or resistance to proteasome inhibitor treatment, which

This will allow researchers to develop automated cancer detection image analysis tools which can be easily distributed to research and clinical users. The platform will also support the

BOTOX is the first and only botulinum toxin product to be approved by the FDA to treat multiple muscle groups of the upper (elbow, wrist, fingers, and thumb)

Dyax is engaged in the development and commercialization of novel biotherapeutics for unmet medical needs. The company is developing DX-2930, a fully humanized monoclonal antibody targeting plasma kallikrein

A statistically significant improvement was demonstrated in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer. It is first phase 3 Vectibix trial

The company is now allowed to use Opdivo in combination with Yervoy (ipilimumab) to treat unresectable or metastatic melanoma across BRAF mutational status. The indication includes both BRAF-wild

Based on this review, the DSMB observed a continued acceptable safety and tolerability profile of Pyridorin in patients with overt diabetic nephropathy. NephroGenex CEO and President Pierre Legault

Oxeia’s lead program, OXE-103, uniquely targets the metabolic injury and energy crisis underlying acute concussion pathology. OXE-103 restores mitochondrial homeostasis via a well-characterized mechanism of action and may